Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1278 participants.
Also called NCT03596450
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,278 participants
- Sponsor
- Registry
-
NCT03596450
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada
- Registry status
- Completed
Technical summary
Registry record NCT03596450. Randomized; no masking; primary purpose treatment. Start 2018-07-13 (actual); primary completion 2022-06-09 (actual). Results posted on 2023-08-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Standard of care
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct03596450- Content hash
72bc57aece213cc9e87130da6f8b0a6552bd2b057e70559be4d993b3e2ad706b